Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundC57Bl6/J wild type and B6.BKS(D) Lepr db/J obese diabetic; FVB-Tg(CAG-luc,-GFP)L2G85Chco/J used as luciferase-expressing cell donorsMalen = n = 5 to 30 animals per condition for wound healing time co…Topical application onto the wound bed, followed by transparent dressing1.5 million B cells per wound in 25 microlitres PBS, select…Immediately after injury for acute wounds; 10 days after wounding for establish…
Model: Splinted full-thickness excisional dorsal skin wounds made with a 5 mm biopsy punch, initial area about 20 mm2, in wild type and obese diabetic mice, including chronic ulcers treated 10 days after wounding
A single topical application of mature naive B cells accelerated acute wound closure by 2 to 3 days in wild type and 5 to 6 days in obese diabetic mice, and closed 43% of established chronic diabetic ulcers versus 5% with saline. Treatment reduced scar size and width, improved reticulated collagen…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.